Development of an integrated approach to cancer disparities: One cancer center's experience

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 11, 2007, Pages 2186-2192

  Emmons, Karen M ^b,d   White, Karen Burns ^a   Benz, Edward J ^c  

^a DANA FARBER HARVARD CANCER CENTER   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CENTER; CANCER CONTROL; CANCER MORTALITY; CANCER PREVENTION; CLINICAL RESEARCH; CONTINUING EDUCATION; EDUCATION PROGRAM; HEALTH CARE POLICY; HEALTH PROGRAM; MEDICAL SERVICE; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROFESSIONAL COMPETENCE;

CANCER CARE FACILITIES; CLINICAL TRIALS AS TOPIC; COMMUNITY-INSTITUTIONAL RELATIONS; COMPETENCY-BASED EDUCATION; DELIVERY OF HEALTH CARE, INTEGRATED; HEALTH STATUS DISPARITIES; HUMANS; MINORITY GROUPS; MINORITY HEALTH; NATIONAL CANCER INSTITUTE (U.S.); NEOPLASMS; UNITED STATES;

EID: 38849131912     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-0211     Document Type: Note

References (12)

1. Institute of Medicine. Unequal treatment: confronting racial and ethnic disparities in health care. Washington (DC): National Academic Press; 2003.
2. Institute of Medicine. Examining the health disparities research plan of the National Institutes of Health: unfinished business. Washington (DC): National Academies Press; 2006.
3. Zheng YL, Loffredo CA, Alberg AJ, et al. Less efficient g2-m checkpoint is associated with an increased risk of lung cancer in African Americans. Cancer Res 2005;65:9566-73.
4. Heist RS, Zhou W, Chirieac LR, et al. MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancer. J Clin Oncol 2007;25:2243-7.
5. Liu G, Gurubhagavatula S, Zhou W, et al. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. Pharmacogenomics J 2007.
6. Ray R, Jepson C, Wileyto P, et al. CREB1 haplotypes and the relative reinforcing value of nicotine. Mol Psychiatry 2007;12:615-7.
7. Lee AM, Jepson C, Hoffmann E, et al. CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. Biol Psychiatry 2007;62:635-41.
8. Munafo MR, Shields AE, Berrettini WH, Patterson F, Lerman C. Pharmacogenetics and nicotine addiction treatment. Pharmacogenomics 2005;6:211-23.
9. Mechanic LE, Bowman ED, Welsh JA, et al. Common genetic variation in TP53 is associated with lung cancer risk and prognosis in African Americans and somatic mutations in lung tumors. Cancer Epidemiol Biomarkers Prev 2007;16:214-22.
10. Neighbors CJ, Rogers ML, Shenassa ED, Sciamanna CN, Clark MA, Novak SP. Ethnic/racial disparities in hospital procedure volume for lung resection for lung cancer. Med Care 2007;45:655-63.
11. Mulligan CR, Meram AD, Proctor CD, Wu H, Zhu K, Marrogi AJ. Unlimited access to care: effect on racial disparity and prognostic factors in lung cancer. Cancer Epidemiol Biomarkers Prev 2006;15:25-31.
12. Mervis J. Biomedical training programs. NIH told to get serious about giving minorities a hand. Science 2006;311:328-9.